Portfolio 1
| Date | Name | Website | Total Raised | Location |
| 09.03.2026 | AN2 Therap... | an2therapeutics.com | $202M | United Sta... |
Mentions in press and media 4
| Date | Title | Description |
| 16.03.2026 | Alto Neuroscience: $120 Million Raised To Advance Treatment-Resistant Depression Drug Candidate | Alto Neuroscience, a clinical-stage biopharmaceutical company developing precision medicines for neuropsychiatric disorders, announced it has secured approximately $120 million in a private placement financing. The financing was led by Comm... |
| 09.03.2026 | AN2 Therapeutics: $40 Million Private Placement Financing Announced | AN2 Therapeutics announced that it has entered into a securities purchase agreement for a private placement expected to generate approximately $40 million in gross proceeds before deducting placement agent fees and other expenses. The finan... |
| 30.10.2024 | GlycoMimetics To Acquire Crescent Biopharma | GlycoMimetics (NASDAQ: GLYC), a Rockville, MD-based late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers, acquired Crescent Biopharma, Inc., a biotechnology company advancing a pipeli... |
| 13.08.2024 | IDRx Raises $120 Million To Transform Cancer Treatment With Precision Therapies | IDRx (a clinical-stage biopharmaceutical company dedicated to transforming cancer treatment with purpose-built precision therapies) announced the completion of an oversubscribed $120 million Series B Preferred Stock financing. This financin... |